EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oligometastatic GIST: Impact of Treatment Modalities and Metastatic Distribution on Overall Survival

Winston Hayes Pearce iD, Nikita Sharma, Leonardo Simonelli, Maiya-Mari Messina, Tanner Hill, Yu-Cherng Channing Chang, Mohammad Saleh, Emily Jonczak, Andrew E Rosenberg, Nipun Merchant, Alan S Livingstone, Dido Franceschi und 4 weitere

Cancers · 14.08.2026 · 18 (16) · 2622

DOI: 10.3390/cancers18162622 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 14.08.2026. Verfasst von Winston Hayes Pearce und 15 weiteren Autor:innen. Beteiligte Einrichtung: Miller School of Medicine, University of Miami, Miami, FL 33136, USA. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Oligometastatic GIST, defined in this study as five or fewer metastatic lesions confined to a single organ, represents a distinct subset with a lower metastatic burden than widely metastatic disease and may have different prognostic and therapeutic considerations.

Methods

We reviewed biopsy-proven oligometastatic GIST diagnosed between August 1998 and June 2025 from a prospectively maintained institutional database, collecting genomic, metastatic, treatment, ethnicity, and survival data. Overall survival (OS), calculated from diagnosis of oligometastatic disease, was estimated by Kaplan–Meier analysis and compared using the log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards regression.

Results

Of 525 subjects with GIST in our database, 96 (18.3%) had oligometastatic GIST (median age: 54 years; median OS from diagnosis of oligometastatic disease: 9.77 years). Most tested tumors were KIT-positive (91.6%), predominantly harboring KIT exon 11 alterations (69.5%). The most common metastatic sites were the liver (n = 44) and peritoneum (n = 37). Overall, 58 patients underwent surgery, including 55 cytoreductive procedures and 3 emergent operations for bleeding or obstruction. Among the cytoreductive procedures, indications included multifocal disease after tyrosine kinase inhibitor (TKI) response (n = 21), unifocal disease after TKI response (n = 18), unifocal progression on TKI (n = 13), and equivocal or undocumented TKI response (n = 3). Overall survival did not differ by liver versus peritoneal metastases (HR: 1.27; 95% CI, 0.59–2.70; p = 0.540) or Hispanic versus non-Hispanic ethnicity (HR: 0.81; 95% CI, 0.34–1.90; p = 0.624). Cytoreductive surgery combined with systemic therapy was associated with longer overall survival than systemic therapy alone (10.8 vs. 7.4 years; HR: 0.44; 95% CI, 0.22–0.89; p = 0.019).

Conclusions

In this retrospective cohort, cytoreductive surgery combined with systemic therapy was associated with longer overall survival than systemic therapy alone.

Schlagwörter

Stichwörter der Autor:innen

gastrointestinal stromal tumormetastasectomymetastasisoligometastasissarcoma

Autor:innen und Institutionen

  • Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
  • Department of Radiology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
  • Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
  • Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA.
  • Department of Pathology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
  • Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.

ORCID-Profile: Winston Hayes Pearce, Julie Grossman

Zitieren

APA

Pearce, W. H., Sharma, N., Simonelli, L., Messina, M. M., Hill, T., Chang, Y. C., Saleh, M., Jonczak, E., Rosenberg, A. E., Merchant, N., Livingstone, A. S., Franceschi, D., Hester, C. A., Grossman, J., Alessandrino, F., & Sylvester Comprehensive Cancer Center Bone and Soft Tissue Sarcomas Team (2026). Oligometastatic GIST: Impact of Treatment Modalities and Metastatic Distribution on Overall Survival. Cancers, 18(16), 2622. https://doi.org/10.3390/cancers18162622

Vancouver

Pearce WH, Sharma N, Simonelli L, Messina MM, Hill T, Chang YC, et al. Oligometastatic GIST: Impact of Treatment Modalities and Metastatic Distribution on Overall Survival. Cancers. 2026;18(16):2622. doi:10.3390/cancers18162622

BibTeX
@article{Pearce2026,
  author = {Pearce, Winston Hayes and Sharma, Nikita and Simonelli, Leonardo and Messina, Maiya-Mari and Hill, Tanner and Chang, Yu-Cherng Channing and Saleh, Mohammad and Jonczak, Emily and Rosenberg, Andrew E and Merchant, Nipun and Livingstone, Alan S and Franceschi, Dido and Hester, Caitlin A and Grossman, Julie and Alessandrino, Francesco and Sylvester Comprehensive Cancer Center Bone and Soft Tissue Sarcomas Team, Sylvester Comprehensive Cancer Center Bone and Soft Tissue Sarcomas Team},
  title = {Oligometastatic GIST: Impact of Treatment Modalities and Metastatic Distribution on Overall Survival},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {16},
  pages = {2622},
  doi = {10.3390/cancers18162622}
}
Kostenlos starten →